Surrozen to Present at Upcoming Healthcare Investor Conferences

Rhea-AI Summary

Surrozen (Nasdaq: SRZN), a biotech company focused on targeted therapeutics that activate the Wnt pathway for tissue repair, has announced its participation in two major healthcare investor conferences. CEO Craig Parker will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 13, 2024, with a fireside chat at 3:00 PM ET, and at the Stifel 2024 Healthcare Conference on November 19, 2024, presenting at 2:25 PM ET. Live audio webcasts will be available through Surrozen's investor website, with recordings archived for later access.

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.

Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024

Fireside Chat at 3:00 PM ET / 12N PT

Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024

Presentation at 2:25 PM ET / 11:25 AM PT

Interested parties may access the live audio webcast for each conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcasts will be archived on the website at www.surrozen.com.

About Surrozen

Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. For more information, please visit surrozen.com.   

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease, as well as the potential benefits of such product candidates), the Company’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales and the potential of TGF-β to be a novel, first-in-class therapeutic to treat the pathology of Idiopathic Pulmonary Fibrosis. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for Sits product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2023 and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 to be filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investor/Media Contact:
Email: Investorinfo@surrozen.com

FAQ

When is Surrozen (SRZN) presenting at the Guggenheim Healthcare Conference in 2024?

Surrozen will present at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 3:00 PM ET / 12N PT.

What time is Surrozen's (SRZN) presentation at the Stifel Healthcare Conference 2024?

Surrozen will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 2:25 PM ET / 11:25 AM PT.

How can investors access Surrozen's (SRZN) conference presentations in November 2024?

Investors can access the live audio webcasts through the Investors section of Surrozen's website at investors.surrozen.com/events-presentations/events-calendar.

What type of therapeutics does Surrozen (SRZN) develop?

Surrozen develops targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration.